市场调查报告书

阿达木单抗的全球市场:2020-2027

Global Adalimumab Market - 2020-2027

出版商 DataM Intelligence 商品编码 968993
出版日期 内容资讯 英文
商品交期: 最快1-2个工作天内
价格
阿达木单抗的全球市场:2020-2027 Global Adalimumab Market - 2020-2027
出版日期: 2020年11月04日内容资讯: 英文
简介

阿达木单抗是一种重组人IgG1单克隆抗体,靶向肿瘤坏死因子(TNF),类风湿性关节炎(RA),幼年特发性关节炎(JIA),牛皮癣关节炎(PsA),强直性脊柱它以Humila品牌被批准用于治疗炎症(AS),克罗恩氏病(CD)和寻常型牛皮癣(Ps)。

市场扩张的驱动力是诸如自身免疫性疾病患病率增加导致对阿达木单抗的需求增加等因素。全球约有4%的人患有自身免疫性疾病,例如类风湿性关节炎,强直性脊柱炎,克罗恩氏病,牛皮癣性关节炎和寻常型牛皮癣。

本报告调查了全球阿达木单抗市场,包括市场动态,行业分析,新冠状病毒感染(COVID-19)的影响分析,疾病类型,分布渠道和地区。提供信息,例如分析,竞争状况和公司概况。

目录

第1章调查方法和范围

第2章市场定义和概述

第3章执行摘要

第4章市场动态

  • 影响市场的因素
    • 促进因素
    • 抑制器
    • 市场机会
    • 影响分析

第5章行业分析

  • 波特的五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 价格分析
  • 监管分析
  • 赎回分析
  • 未满足的需求

第6章COVID-19的影响分析

  • 分析Covid-19对市场的影响
    • COVID-19之前的市场情景
    • COVID-19大流行期间的市场情景
    • COVID-19或未来方案
  • 大流行期间的价格趋势
  • 供求状况
  • 国家政府在大流行期间与市场有关的举措
  • 制造商的战略计划
  • 结论

第7章市场分析:按疾病类型

  • 简介
  • 市场规模和同比增长率分析
  • 市场吸引力指数
    • 类风湿关节炎(RA)*
    • 银屑病关节炎(PsA)
    • 克隆疾病(CD)
    • 滋补性脊柱炎(AS)
    • 寻常型牛皮癣(Ps)
    • 溃疡性结肠炎
    • 其他

第8章市场分析:按分销渠道

  • 简介
  • 市场规模和同比增长率分析
  • 市场吸引力指数
    • 医院药房*
    • 零售药房
    • 在线药房
    • 其他

第9章市场分析:按地区

  • 简介
  • 市场规模和同比增长率分析
  • 市场吸引力指数
  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第10章竞争情况

  • 竞争情景
  • 市场定位/份额分析
  • 并购分析

第11章公司简介

  • AbbVie Inc.*
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals
  • Hetero Healthcare Limited
  • Novartis AG
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Mylan N.V
  • Emcure Pharmaceuticals Ltd.
  • Cipla Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co Ltd.
  • Terumo Corp.
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.

第12章 主要调查结果

第13章 关于DataM Intelligence

目录

Market Overview

Adalimumab is approved under the brand name Humira for the treatment of the Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn's Disease (CD), and Plaque Psoriasis (Ps). Adalimumab is a recombinant human IgG 1 monoclonal antibody that targets tumor necrosis factor (TNF). It acts by binding to the tumor necrosis factor (TNF) and inhibiting the its interaction with the p55 and p75 cell surface TNF receptors. It lyses surface tumor necrosis factor expressing cells. It is effective in modulating the biological responses induced or regulated by TNF involving the changes in the levels of adhesion molecules responsible for leukocyte migration.

Adalimumab is developed by using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system. It is supplied as either a single-use, prefilled pen or as single-use, 1 mL filled glass syringe.

The global adalimumab market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Market Dynamics

Rising Prevalence of Autoimmune Disorders is Driving the Growth of the Market

The market is driven by the increasing demand for the adalimumab with the increasing prevalence of the autoimmune diseases. According to the National Stem Cell Foundation (NSCF), approximately 4% of the world's population is suffering from one of autoimmune diseases. Rheumatoid arthritis, ankylosing spondylitis, crohn's disease, psoriatic arthritis, plaque psoriasis, and others are the most common autoimmune diseases. According to National Psoriasis Foundation, approximately 2% to 3% of the global population i.e., 125 million people are suffering from Psoriasis worldwide. Approximately, 30% of patients with Psoriasis develop psoriatic arthritis, a chronic inflammatory arthritis that leads to joint deformations and disability. Ankylosing spondylitis affects around 0.1% and 1.4% of people worldwide. It is most frequent in men in comparison to the women. According to the Arthitis Foundation, around 80% of people develops the symptoms of ankylosing spondylitis in age-group at or before age of 30 years. Around, 5% of patients would develop ankylosing spondylitis in age-group of 45 or older.

Favorable Reimbursement Coverage for Adalimumab is Boosting the Market Growth

The better availability of the reimbursement coverage for adalimumab shall stimulate the market growth. Around, 99% of national commercial, Medicare Part D, and Medicaid patients covers the adalimumab. Chinese regulators had also included adalimumab to the country's National Reimbursement Drug List (NRDL). Chinese regulators provide e an average of 61% in price cuts of adalimumab with pharma companies.

Adverse Effects Associated with the use of Adalimumab is Hampering the Market Growth

The market is hindered by the adverse effects associated with the use of the adalimumab. Several adverse effects such as nausea, abdominal pain, hyperlipidemia, hematuria, hypercholesterolemia, back pain, rash, headache, hypertension, and others are observed among the patients. Redness, swelling or pain is observed at the site of injection of the adalimumab. It also increases the risk of developing the fungal, bacterial, and viral infection that can spread through the body. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergilosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been observed among the patients treated with adalimumab.

COVID-19 Impact Analysis

The global adalimumab market has received immense impetus from the COVID-19 pandemic, as several institutes, organizations, and companies are focussing on evaluating the potential of adalimumab for the treatment of the COVID-19. There is increasing research and development activities for adalimumab for the COVID-19. It has been observed that the Covid-19 patients who had adminstered the anti-TNF therapies for the treatment of inflammatory bowel disease and inflammatory arthritis were less likely to be hospitalised. The anti-TNF therapies is effective in neutralisizing the TNF, a major component of the cytokine response part of the damaging excess inflammatory phase of COVID-19. Therefore, institutes, and organizations are focussing on conducting the clinical trials for examining the efficacy and safety of adalimumab among the patients with COVID-19. For instance, in October 2020, Researchers at the University of Oxford in the United Kingdom had planned to initiate a new clinical trial to evaluate the effectiveness of the adalimumab for the treatment of the COVID-19 patients in the community care settings, primarily in care homes. The clincial trial i.e., AVID-CC would be led by the Oxford Clinical Trials Research Unit (OCTRU) and would enrol up to 750 patients from community care homes.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, the prevalence of the Rheumatoid Arthritis (RA) was found to be 395.5 per 100,000 in the United States in 2017. Women are two to three times as likely to be affected in comparision to the men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Segment Analysis

Rheumatoid Arthritis segment is expected to hold the largest share in the Adalimumab market

By disease type, the market is classified as the rheumatoid arthritis, psoriatic arthritis, crohn's disease, ulcerative colitis, and others. The rheumatoid arthritis segment is anticipated to hold the largest share in the adalimumab treatment market. Rheumatoid arthritis is the most common autoimmune arthritis that affects the joints, connective tissues, muscle, tendons, and fibrous tissues. It is characterized by the joint pain, stiffness, swelling and decreased movement of the joints. It causes pain and swelling in the wrist and small joints of the hand and feet. Rheumatoid Arthritis can hamper the patient's mobility and lead to the permanent joint damage. The prevalence of rheumatoid arthritis is increasing worldwide. According to the World Health Organization (WHO), the prevalence of the rheumatoid arthritis ranges between the 0.3% and 1% across the globe. It is most frequent among the women in comparison to the men.

By Distribution Channel, Hospital Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified based on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies is segmented to have the highest market growth due to the high availability of the adalimumab in the hospital pharmacies. There is growing usage of the adalimumab for the treatment of the autoimmune and skin disorders in the hosptials. Adalimumab is effective in reducing the pain, and swelling associated with the several disorders.

Geographical Analysis

North America region holds the largest market share global Adalimumab market

North America region is dominating the global adalimumab market accounted for the largest market share in 2019 owing to the high prevalence of the Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, Plaque Psoriasis, and Ulcerative Colitis. According to the National Psoriasis Foundation, around one million people are being affected by Psoriatic Arthritis in the United States. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Plaque Psoriasis is the most frequent form of psoriasis that affects around 6.7 million adults in the United States. As per the National Institute of Health, the prevalence of Crohn's Disease was 201 per 100,000 in the United States.

The United States accounts for the highest market share due to the availability of the favorable reimbursement coverage for adalimumab. There is presence of the several market players developing adalimumab. There is increasing research and development activities for examining the potential of adalimumab for the treatment of other indications apart from the Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis. The availability of the advanced healthcare facilities and infrastructure shall stimulate the market over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global adalimumab market owing to the increasing prevalence of the autoimmune diseases with the increasing adoption of unhealthy lifestyle, stress in daily life & immune system malfunction. The growing elder population shall have positive impact on the market. According to the United Nations Report, there were around 87 million of population of age-group 65 years or over in India. There is increasing investment for the improvement of the healthcare facilities & infrastructure. There is increasing awareness regarding the autoimmune diseases shall have a positive impact on the market.

There is increase in the approval of the biosimilars of adalimumab due to the presence of favorable regulatory policies for biosimilars. For instance, in September 2020, Innovent Biologics, Inc. had received the approval for Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug from the National Medical Products Administration (NMPA) of China for the treatment of Rheumatoid Arthritis (RA), ankylosing spondylitis and psoriasis in China. The increasing domestic income and purchasing power of people shall boost the demand for adalimumab over the forecasted period.

Competitive Landscape

The adalimumab market studied is a fragmented market with the presence of large number of market players. AbbVie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals, Novartis AG, and Pfizer Inc are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

  • In September 2020, Sensyne Health plc had entered into the collaboration with the University of Oxford for conducting the clinical trial for evaluating the adalimumab for the treatment of COVID-19. Under the terms of agreement, Sensyne would provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19
  • In May 2018, Orion Corporation had entered into the collaboration with the Amgen to commercialize Amgevita (biosimilar adalimumab) in Finland

Product Launch & Approvals:

  • In November 2018, Amgen Inc. had received the approval from the United States Food and Drug Administration (FDA) Abrilada (adalimumab-afzb) as a biosimilar to Humira (adalimumab) for the treatment of certain patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis
  • In October 2018, Amgen had launched the Amgevita, a biosimilar to adalimumab, will launch in markets across Europe. Amgevita is recommended for the treatment of the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa; non-infectious intermediate, posterior and panuveitis, moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. It is also used for the treatment of treatment of pediatric inflammatory diseases, including moderate-to-severe Crohn's disease, severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis
  • In August 2017, Boehringer Ingelheim Pharmaceuticals had received the approval for the Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases including the moderate to severe active Rheumatoid Arthritis (RA), moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis

Acquisition:

  • In May 2020, AbbVie had acquired the Allergan plc

Partnership:

  • In March 2020, Alvotech HF had entered into an exclusive license partnership with DKSH for the commercialization of AVT02, a biosimilar to AbbVie's HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets
  • In April 2018, Mylan N.V. had entered into the partnership with the Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to Humira (adalimumab) developed by Fujifilm Kyowa Kirin Biologics. Mylan would leverage its regulatory platform to seek approval and commercialize the product in Europe

Why Purchase the Report?

  • Visualize the composition of the adalimumab market segmentation by disease type, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in adalimumab market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of adalimumab market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global adalimumab market report would provide an access to an approx. 61 market data table, 58 figures and 230 pages.

Target Audience 2022

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Adalimumab Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Adalimumab Market - Market Definition and Overview

3. Global Adalimumab Market - Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Global Adalimumab Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Autoimmune Disorders
      • 4.1.1.2. Favorable Reimbursement Coverage
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Adverse Effects Associated with the Use of Adalimumab
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Adalimumab Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. Global Adalimumab Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Adalimumab Market - By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Rheumatoid Arthritis (RA)*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Psoriatic Arthritis (PsA)
    • 7.3.3. Crohn's Disease (CD)
    • 7.3.4. Ankylosing Spondylitis (AS)
    • 7.3.5. Plaque Psoriasis (Ps)
    • 7.3.6. Ulcerative Colitis
    • 7.3.7. Others

8. Global Adalimumab Market - By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospitals Pharmacies*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others

9. Global Adalimumab Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Global Adalimumab Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Adalimumab Market- Company Profiles

  • 11.1. AbbVie Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Amgen Inc.
  • 11.3. Boehringer Ingelheim International GmbH
  • 11.4. Bristol-Myers Squibb Company
  • 11.5. Cadila Healthcare Ltd.
  • 11.6. F. Hoffmann-La Roche Ltd.
  • 11.7. Glenmark Pharmaceuticals
  • 11.8. Hetero Healthcare Limited
  • 11.9. Novartis AG
  • 11.10. Pfizer Inc.
  • 11.11. Torrent Pharmaceuticals Ltd.
  • 11.12. Mylan N.V
  • 11.13. Emcure Pharmaceuticals Ltd.
  • 11.14. Cipla Inc.
  • 11.15. Reliance Life Sciences
  • 11.16. Samsung Bioepis Co Ltd.
  • 11.17. Terumo Corp.
  • 11.18. Fujifilm Kyowa Kirin Biologics Co. Ltd.

LIST NOT EXHAUSTIVE

12. Global Adalimumab Market - Premium Insights

13. Global Adalimumab Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us